Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis

Key Points

• Dupilumab treatment restores the epithelial barrier in both lesional and nonlesional skin.
• The restoration of the barrier occurs in children with atopic dermatitis over a specified treatment duration.
• Observational analysis measured skin barrier integrity and inflammation reduction in affected areas.
• Highlights the potential for dupilumab to improve skin health in pediatric patients with atopic dermatitis.